Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.43 |
| ▸ | UGCG | Q16739 | 2/20 | 0.43 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13339427 | 0.92 | GBA1 (0.40) | GBA1UGCGGBA2MEN1KMT2A | |
| SCHEMBL13367174 | 0.83 | GBA1 (0.42) | GBA1UGCGGBA2MEN1KMT2A | |
| SCHEMBL13339415 | 0.81 | MEN1 (0.36) | GBA1UGCGGBA2MEN1KMT2A | |
| SCHEMBL13749926 | 0.74 | GBA1 (0.38) | GBA1UGCGGBA2MEN1KMT2A | |
| SCHEMBL9815022 | 0.73 | ALDH1A1 (0.48) | GBA1UGCGGBA2MEN1KMT2A | |
| SCHEMBL13951802 | 0.73 | GBA1 (0.52) | GBA1UGCGGBA2MEN1KMT2A | |
| SCHEMBL27743245 | 0.73 | KMT2A (0.43) | GBA1UGCGGBA2MEN1KMT2A | |
| SCHEMBL901166 | 0.73 | KMT2A (0.50) | GBA1UGCGGBA2MEN1KMT2A | |
| SCHEMBL20827637 | 0.72 | ALDH1A1 (0.44) | GBA1UGCGGBA2MEN1KMT2A | |
| SCHEMBL13951801 | 0.72 | GBA1 (0.54) | GBA1UGCGGBA2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121056-A1 | PSEUDONUCLEOTIDE COMPRISING AN INTERCALATOR | HUMAN GENETIC SIGNATURES PTY. LTD. (AU) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121056-A1 | PSEUDONUCLEOTIDE COMPRISING AN INTERCALATOR | POLRMT, POLN, RNASE1 | GBA1 1113/4885UGCG 1446/4885GBA2 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.